Bicycle Therapeutics (BCYC)
NASDAQ:BCYC
Want to see BCYC full AI Analyst Report?
BCYC Stock Chart & Stats
$5.33
-$0.24(-1.59%)
At close: 4:00 PM EST
$5.33
-$0.24(-1.59%)
Day’s Range― - ―
52-Week Range$3.95 - $9.18
Previous CloseN/A
Volume92.63K
Average Volume (3M)466.09K
Market Cap
$278.83M
Enterprise Value-$263.78M
Total Cash (Recent Filing)$559.47M
Total Debt (Recent Filing)$15.34M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.15
Shares Outstanding50,373,280
10 Day Avg. Volume828,290
30 Day Avg. Volume466,092
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)0.80
Price to Sales (P/S)6.76
P/FCF Ratio-1.94
Enterprise Value/Market Cap-0.95
Enterprise Value/Revenue-4.15
Enterprise Value/Gross Profit35.02
Enterprise Value/Ebitda1.25
Forecast
1Y Price Target
$10.20Price Target Upside91.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.28
Revenue Forecast (FY)$23.68M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low reported leverage materially reduces financial risk and gives management flexibility to fund clinical programs, negotiate partnerships, or bridge to milestones without immediate refinancing. This balance-sheet strength lengthens runway versus highly levered peers and supports strategic optionality.
Positive Duravelo‑2 Phase 2 Clinical DataRobust Phase 2 signals and a favorable safety profile offer structural de-risking of the lead program, improving the likelihood of partnership, milestone payments, or late‑stage funding. Durable clinical validation strengthens the commercial case and underpins long-term value capture if confirmatory trials succeed.
EphA2 Program And Platform DifferentiationProgress in EphA2 and imaging/xenograft data highlight the Bicycle platform's versatility across targets and modalities, reducing single‑asset binary risk. A differentiated platform that can address multiple tumor types enhances partnering appeal and creates multiple long‑term value pathways beyond one program.
Bears Say
High Cash Burn / Weak Cash GenerationSustained negative operating and free cash flow requires recurring external financing, increasing dilution or restrictive deal terms. Persistent cash burn constrains the company’s ability to self‑fund large Phase 3 programs, pressuring capital allocation and potentially forcing prioritization of programs over long horizons.
Deep Operating Losses / Negative ProfitabilityLarge and persistent operating losses erode equity and limit internal reinvestment capacity. Without a clear path to breakeven, management faces structural pressure to secure partnerships or dilution, which can dilute long‑term shareholder upside and constrain strategic independence for pivotal trials.
Revenue Volatility & Partner-dependent ModelReliance on collaboration, milestone and R&D funding creates lumpy, unpredictable revenue that complicates multi‑year planning. Revenue volatility increases execution risk for sustained R&D programs, heightens dependency on partner timelines, and makes steady organic funding of late‑stage development uncertain.
Bicycle Therapeutics News
BCYC FAQ
What was Bicycle Therapeutics’s price range in the past 12 months?
Bicycle Therapeutics lowest stock price was $3.95 and its highest was $9.18 in the past 12 months.
What is Bicycle Therapeutics’s market cap?
Bicycle Therapeutics’s market cap is $278.83M.
When is Bicycle Therapeutics’s upcoming earnings report date?
Bicycle Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 45 days.
How were Bicycle Therapeutics’s earnings last quarter?
Bicycle Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.621 by -$0.249.
Is Bicycle Therapeutics overvalued?
According to Wall Street analysts Bicycle Therapeutics’s price is currently Undervalued.
Does Bicycle Therapeutics pay dividends?
Bicycle Therapeutics does not currently pay dividends.
What is Bicycle Therapeutics’s EPS estimate?
Bicycle Therapeutics’s EPS estimate is -0.56.
How many shares outstanding does Bicycle Therapeutics have?
Bicycle Therapeutics has 50,373,280 shares outstanding.
What happened to Bicycle Therapeutics’s price movement after its last earnings report?
Bicycle Therapeutics reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.621. Following the earnings report the stock price went down -0.211%.
Which hedge fund is a major shareholder of Bicycle Therapeutics?
Currently, no hedge funds are holding shares in BCYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicycle Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.20 (91.37% Upside)
$10.20 (91.37% Upside)
Hedge Fund Trend
Increased
By 63.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $68.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.8%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.01%
12-Months-Change
Fundamentals
Return on Equity
-35.74%
Trailing 12-Months
Asset Growth
-26.19%
Trailing 12-Months
Company Description
Bicycle Therapeutics
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.
BCYC Stock 12 Month Forecast
Average Price Target
$10.20
▲(91.37% Upside)
Technical Analysis
Ownership Overview
23.08% Insiders
5.45% Mutual Funds
55.30% Other Institutional Investors
15.18% Public Companies and
Individual Investors